Phathom Pharmaceuticals Stock Today
| PHAT Stock | USD 6.23 0.03 0.48% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Phathom Pharmaceuticals is selling for under 6.23 as of the 22nd of March 2025; that is 0.48 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 6.06. Phathom Pharmaceuticals has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. The company has 69.64 M outstanding shares of which 14.86 M shares are at this time shorted by private and institutional investors with about 13.68 trading days to cover. More on Phathom Pharmaceuticals
Moving together with Phathom Stock
Phathom Stock Highlights
| CEO President | Terrie Curran |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Phathom Pharmaceuticals (PHAT) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Florham Park, NJ, United States, 07932 and employs 427 people. Phathom Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 437.68 M. Phathom Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 69.64 M outstanding shares of which 14.86 M shares are at this time shorted by private and institutional investors with about 13.68 trading days to cover.
Phathom Pharmaceuticals currently holds about 207.39 M in cash with (266.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39.
Check Phathom Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationPhathom Pharmaceuticals owns a total of 69.64 Million outstanding shares. The majority of Phathom Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Phathom Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Phathom Pharmaceuticals. Please pay attention to any change in the institutional holdings of Phathom Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost five hundred fourty-three thousand one hundred sixty-nine invesors are currently shorting Phathom Pharmaceuticals expressing very little confidence in its future performance.
Check Phathom Ownership Details
Phathom Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Phathom Pharmaceuticals market risk premium is the additional return an investor will receive from holding Phathom Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.2848 | |||
| Treynor Ratio | (0.11) |
Phathom Stock Against Markets
Phathom Pharmaceuticals Corporate Management
| Anthony Guzzo | Chief Officer | Profile | |
| Joseph JD | Chief Officer | Profile | |
| Tom Harris | Chief Officer | Profile | |
| Martin Gilligan | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile | |
| David Socks | CoFounder Director | Profile |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.